SecureCell «at a glance»

• Development of a method for the production of autologous insulin producing cells for diabetes therapy, making conventional insulin therapy obsolete.
• Has acquired leading products and technologies for bioprocess technology (cell cultivation) enabling short-term profitable operations …
• … and explores these unparalleled technologies long-term to develop unique methods for stem cell differentiation
• Exploring additional market potential in other therapeutic areas (MS, stroke, wound healing, cardiovascular diseases, and many more) through out-licensing of stem cell technology …
• Five years ahead of the potential competitors
• Market volume (bioprocess technology): 2.8 billion USD
  Market volume (diabetes therapy): 27 billion USD (Insulin)